Clinical trial protocol for Rye hull extract

Evaluation test of the effect of alkylresorcinol contained in rye husk extract on humans

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1030210671

Enrollment

Registered

2022-03-17

Start date

2021-01-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-alcoholic steatohepatitis preventive effect test in health conditios with high hepatitis marker. Non-alcoholic steatohepatitis

Interventions

A cracker containing a rye extract containing 2 grams of alkylresorcinol as a constituent lipid is fed once a day.

Alkylresorcinol

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Healthy individuals with a body mass index (BMI) value of 23 or higher.

Exclusion criteria

Exclusion criteria: Recipient of a diabetes or hepatitis drug.

Design outcomes

Primary

Measure	Time frame
Body weight, abdominal circumference, blood triglyceride level, blood cholesterol level, blood AST level, blood ALT level, blood sugar level	—

Secondary

Measure	Time frame
Bristol stool scale and Stool frequency.	—

Contacts

Public ContactShinjiro Imai

Tokyo University of Technology

imaishi@stf.teu.ac.jp+81-42-637-2584

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026